User profiles for ANTONIO MARCHESONI
Marchesoni AntonioReumatologo, Humanitas, Milano Verified email at sanpiox.humanitas.it Cited by 11482 |
Classification criteria for psoriatic arthritis: development of new criteria from a large international study
…, D Gladman, P Helliwell, A Marchesoni… - … : Official Journal of …, 2006 - Wiley Online Library
Objective. To compare the accuracy of existing classification criteria for the diagnosis of
psoriatic arthritis (PsA) and to construct new criteria from observed data. Methods. Data were …
psoriatic arthritis (PsA) and to construct new criteria from observed data. Methods. Data were …
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
…, YJ Lee, E Lubrano, A Marchesoni… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in …
…, R Gorla, M Govoni, G Lapadula, A Marchesoni… - Autoimmunity …, 2012 - Elsevier
OBJECTIVE: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF
therapy on the basis of the data included in the GISEA register. METHODS: The study …
therapy on the basis of the data included in the GISEA register. METHODS: The study …
Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis
Background Psoriatic arthritis (PsA) is a specific form of inflammatory arthritis associated with
psoriasis affecting in the same measure men and women but with a consistent geographic …
psoriasis affecting in the same measure men and women but with a consistent geographic …
A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.
…, P Macchioni, I Olivieri, A Marchesoni… - The Journal of …, 2001 - jrheum.org
OBJECTIVE: To compare the efficacy and tolerability of cyclosporine (CSA) with that of
symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA)…
symptomatic therapy (ST) alone and sulfasalazine (SSZ) in the treatment of psoriatic arthritis (PsA)…
Serious infections during anti-TNFα treatment in rheumatoid arthritis patients
…, FB Pallavicini, R Gorla, M Filippini, A Marchesoni - Autoimmunity …, 2009 - Elsevier
The objective was to estimate the incidence of serious infections in the patients treated with
anti-TNFα agents for rheumatoid arthritis (RA) recorded in the Lombardy Rheumatology …
anti-TNFα agents for rheumatoid arthritis (RA) recorded in the Lombardy Rheumatology …
TNF‐α antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
A Marchesoni, E Zaccara, R Gorla… - Annals of the New …, 2009 - Wiley Online Library
A cohort of rheumatoid arthritis (RA) patients in the Lombardy Rheumatology Network (LOHREN)
registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, and 36 months. …
registry and receiving anti‐TNF therapy was evaluated after 6, 12, 24, and 36 months. …
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study
…, C Sardu, I Ujfalussy, R Scarpa, A Marchesoni… - The Journal of …, 2011 - jrheum.org
Objective. During OMERACT 8, delegates selected patient global assessment (PGA) of
disease as a domain to be evaluated in randomized controlled trials in psoriatic arthritis (PsA). …
disease as a domain to be evaluated in randomized controlled trials in psoriatic arthritis (PsA). …
Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal
…, FB Pallavicini, M Filippini, R Gorla, A Marchesoni… - Autoimmunity …, 2009 - Elsevier
It has been found that tumour necrosis factor(TNF)-alpha plays a pivotal role in the pathogenesis
of rheumatoid arthritis (RA), and the development of drugs targeting this molecule has …
of rheumatoid arthritis (RA), and the development of drugs targeting this molecule has …
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of …
Objective. To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors
adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (…
adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (…